

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
August 8, 2016**

**ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES ACT OF 1933 AND THE
SECURITIES EXCHANGE ACT OF 1934**

**Accelaron Pharma Inc.
File Nos. 333-190417 and 001-36065
CF#33985**

Accelaron Pharma Inc. submitted an application under Rules 406 and 24b-2 requesting an extension of a previous grant of confidential treatment for information it excluded from Exhibits 10.6, 10.7 and 10.8 to a Form S-1 filed on August 7, 2013, as amended, as modified by Exhibits 10.6 and 10.8 refiled with fewer redactions as Exhibits 10.1 and 10.3 to a Form 10-Q filed on August 4, 2016.

Based on representations by Accelaron Pharma Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

Exhibit 10.6 to Form S-1 filed August 7, 2013	through July 3, 2019
Exhibit 10.7 to Form S-1 filed August 7, 2013	through July 3, 2019
Exhibit 10.8 to Form S-1 filed August 7, 2013	through July 3, 2019
Exhibit 10.1 to Form 10-Q filed August 4, 2016	through July 3, 2019
Exhibit 10.3 to Form 10-Q filed August 4, 2016	through July 3, 2019

For the Commission, by the Division of Corporation Finance, pursuant to Delegated Authority:

Brent J. Fields
Secretary